Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient

Mandavia, Divyesh; Virpariya, Mukund M.; Patel, Tejas; Tripathi, Chandra Bhushan

doi:10.2174/157488612802715744

Cited by 8 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a classical surge in the serum insulin levels with a subsequent decrease in the blood glucose levels. Though there are reports of dysglycemia regarding the use of fluoroquinolones in treating different ailments with quinolones, previous case studies reported that quinolones induce dysglycemia [ 17 , 18 , 19 , 20 ]. However, there are also reports of hyperglycemia with Moxifloxacin , Gatifloxacin , and levofloxacin .…”

Section: Discussionmentioning

confidence: 99%

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

et al. 2022

View full text Add to dashboard Cite

Fluoroquinolones (FQs) have been reported to cause dysglycemia in both diabetic and non-diabetic patients. However, diabetic patients are usually on polypharmacy, so we cannot attribute the dysglycemia specifically to FQs. To answer the question as to whether Moxifloxacin and Gemifloxacin influence blood glucose levels and serum insulin levels or otherwise, rabbits were used as experimental animals in an in vivo model followed by a phase I randomized clinical trial in euglycemic healthy volunteers. The effects on the serum insulin and blood glucose levels in the Moxifloxacin and Gemifloxacin treated groups were, respectively, determined on the fifth day in both the in-vivo rabbits model and in the test subjects of the phase I clinical trial. The effects of these drugs were also checked on the histomorphology of the pancreas in the rabbits. The findings of our study suggest that Moxifloxacin and Gemifloxacin significantly (p < 0.05) reduced the blood glucose levels via a subsequent significant shift in the serum insulin levels both in the in vivo animal model and in the test subjects of the phase I clinical trial. No prominent effects on the beta cells histomorphology were noted in this study. Moxifloxacin showed a more significant effect than Gemifloxacin. The insulinotropic effect was comparable to the effect of Glibenclamide. It is concluded that Moxifloxacin and Gemifloxacin have a significant blood glucose lowering effect mediated through insulinotropic action. (Clinical Trials.gov identifier: NCT04692623).

show abstract

Section: Discussionmentioning

confidence: 99%

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although the metabolism of paracetamol can be decreased when combined with MOXI, if you need a pain killer it is however fine to take paracetamol with MOXI. For example, patients receiving 200 mg MOXI orally each half day could also take 500 mg paracetamol in case of dry cough and high fever rate [10]. So, the simultaneous detection of MOXI and paracetamol is of interest.…”

Section: Resultsmentioning

confidence: 99%

A Sensitive Electrochemical Sensor for Moxifloxacin Hydrochloride Based on Nafion/Graphene Oxide/Zeolite Modified Carbon Paste Electrode

et al. 2020

View full text Add to dashboard Cite

A carbon paste electrode (CPE) modified with Nafion, Graphene oxide and zeolite has been prepared and characterized, and the resulting Nafion/Graphene oxide/Zeolite modified carbon paste electrode (N/G/Z/MCPE) has been applied to the electrochemical detection of Moxifloxacin hydrochloride (MOXI). It exhibited a good electrocatalytic activity in phosphate buffer (optimum at pH 7.4), as pointed out by cyclic voltammetry (CV), and N/G/Z/MCPE can be exploited for MOXI detection by chronoamperometry, electrochemical impedance spectroscopy and differential pulse voltammetry. This latter was the most sensitive one and gave rise to a linear calibration curve in the 0.04 to 250 μM concentration range, with limits of detection and qualification estimated at 1.0 nM and 3.3 nM, respectively. Contrary to previous electrochemical sensors for MOXI (e. g., CPE modified with metal nanoparticles), this new sensor can be used for multiple successive analyses without needing to refresh its surface.

show abstract

“…[234] In the literature there are only two case reports of moxifloxacin induced hypoglycemia. [56] These were published in last 1 year and the patients were non-diabetic.…”

Section: Discussionmentioning

confidence: 99%